Obiltoxaximab (ETI 204) is a highly potent monoclonal antibody targeting the protective antigen (PA) component of Bacillus anthracis, the bacterium responsible for anthrax. This antibody is critical in disrupting the assembly of anthrax toxin, thereby preventing the intoxication of target cells. Demonstrating efficacy in animal models, Obiltoxaximab enhances survival rates and impedes the peripheral dissemination of the bacteria. It is primarily utilized in research focused on inhalational anthrax, as well as associated bacteremia and toxemia. This makes Obiltoxaximab an essential tool for studies aimed at understanding and mitigating the pathogenic mechanisms of anthrax.
Obiltoxaximab (ETI 204) is a highly potent monoclonal antibody targeting the protective antigen (PA) component of Bacillus anthracis, the bacterium responsible for anthrax. This antibody is critical in disrupting the assembly of anthrax toxin, thereby preventing the intoxication of target cells. Demonstrating efficacy in animal models, Obiltoxaximab enhances survival rates and impedes the peripheral dissemination of the bacteria. It is primarily utilized in research focused on inhalational anthrax, as well as associated bacteremia and toxemia. This makes Obiltoxaximab an essential tool for studies aimed at understanding and mitigating the pathogenic mechanisms of anthrax.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
